Clinical trials located in

Cagliari

Cagliari city is located in Italy. Currently, 9 clinical trials are being conducted in this city.

Cagliari, the capital of Sardinia, Italy, boasts a rich tapestry of history and culture. Nestled along the southern coast, it’s a city where ancient ruins meet modern life. The heart of Cagliari is its Castello district, a medieval walled quarter perched on a hill, offering panoramic views of the Gulf of Cagliari. Noteworthy is the Punic and Roman archaeological site of Tuvixeddu, showcasing the island’s ancient past. The city’s vibrant markets, like the Mercato di San Benedetto, reflect its deep-rooted culinary traditions. Cagliari is also a haven for flamingos, which flock to its surrounding wetlands, adding a splash of color to its scenic landscapes.

  • CT-EU-00114975

    Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • Long-term safety evaluation of luspatercept treatment

    The study focuses on patients with myeloproliferative neoplasms. It tests the drug Luspatercept (ACE-536), evaluating its safety and efficacy over a long term compared to a placebo. This study assessing the prolonged safety of luspatercept in individuals previously enrolled in luspatercept studies. The trial involves multiple phases, including an initial assessment and a follow-up period, where the effects of Luspatercept on the disease’s progression and symptoms are closely monitored. This helps determine if the drug can significantly improve the condition or quality of life for those affected by these neoplasms.

    • Luspatercept
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study on Tolebrutinib’s ability to delay disability progression in multiple sclerosis

    This is a study that involves a specific type of multiple sclerosis (MS) called primary progressive multiple sclerosis (PPMS). In this study, a drug called SAR442168, also known as Tolebrutinib, will be tested against a placebo. The main purpose of the study is to see if this drug can slow down the progression of disability in PPMS. The researchers will also look at the drug’s effect on clinical markers, brain images (MRI), thinking abilities, physical function, and quality of life. They will also consider the safety and tolerability of this drug. How long each person will take the drug can vary, but it will be somewhere between 12 and 60 months.

    • Tolebrutinib/SAR442168
  • Examining new dosing of belantamab for resistant multiple myeloma

    The study is called DREAMM-14 and is intended for people with a disease called multiple myeloma that does not respond to other treatments. Scientists are investigating various possible uses of a drug called belantamab mafodotin. They want to see if changing the dose of the drug or the frequency of its administration can fight the disease more effectively and cause fewer side effects. They will also look at changes in your vision and the condition of the cornea (the clear front part of the eye) on a scale of 0 to 4. This scale assesses the condition of the cornea and any changes in vision, with 0 being no change and 4 being a major change. Doctors will measure how many people experience corneal changes, how long they last, and whether the events are related to the amount of medication they take. They will also look at how the disease responds to the medicine and how long it takes to take treatment.

    • Belantamab mafodotin
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • Testing effectiveness of hydrocortisone acetate suppositories for ulcerative colitis

    This trial involves the administration of hydrocortisone acetate suppositories to treat ulcerative colitis in the rectum—an inflammation of the bowel. The study covers adults over 18 years of age. This scientific method ensures unbiased results. Over a span of 28 days, participants will receive a rectal suppository in the morning and evening. The trial aims to measure the safety and effectiveness of the administered drug compared to a placebo. The final goal is to alleviate the symptoms of ulcerative colitis and improve the quality of life for patients suffering from this condition.

    • Hydrocortisone acetate

See more clinical trials in other cities in Italy:

.